The Medicines Company has entered into an agreement with Sandoz to launch the generic version of Angiomax (bivalirudin) for injection.

Angiomax is an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. Angiomax is also indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin.

RELATED: Novel Antiplatelet Agent Gets FDA Approval

Angiomax is currently available as a 250mg/vial strength in single-use vials.

For more information call (800) 388-1189 or visit